CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...